Digestive Health

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

Chronic fatigue is a related symptom with inflammatory bowel disease (IBD).

Although small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) share many of the same symptoms, SIBO affects the small intestine and IBS affects the large intestine.

Inflammatory conditions such as celiac disease can require care consideration and monitoring to manage iron deficiency

The primary end point of clinical remission at week 26 was met, with 36.7% of individuals treated with RHB-104 achieving clinical remission.

A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.

Unique gut flora were found in children with autism spectrum disorder (ASD).

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Dedicated clinical trials in IBD cohorts that scrutinized biosimilar use in real-world clinical practice have direct implications on decision making.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.

Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.

The vitamin improved lipid metabolism to slow the progression of the disease.

The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE.

Patients who are immunocompromised generally had worse risk and severity of CDI.

According to the authors, identifying the degree of disagreement with physicians’ deprescribing recommendations can improve the communication among older adults and their physicians.

The effects of probiotic strains on both constipation and cognition among all individuals involved in a meta-analysis remains difficult to determine.

Social jet lag could create adverse health impacts that a 90-minute difference in the mid-point of sleep can improve.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.